Heat-Shock Proteins in Leukemia and Lymphoma: Multitargets for Innovative Therapeutic Approaches.
Fiche publication
Date publication
février 2023
Journal
Cancers
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GARRIDO Carmen, Dr QUERE Ronan, Pr GIRODON François, Dr JEGO Gaëtan
Tous les auteurs :
Cabaud-Gibouin V, Durand M, Quéré R, Girodon F, Garrido C, Jego G
Lien Pubmed
Résumé
Heat-shock proteins (HSPs) are powerful chaperones that provide support for cellular functions under stress conditions but also for the homeostasis of basic cellular machinery. All cancer cells strongly rely on HSPs, as they must continuously adapt to internal but also microenvironmental stresses to survive. In solid tumors, HSPs have been described as helping to correct the folding of misfolded proteins, sustain oncogenic pathways, and prevent apoptosis. Leukemias and lymphomas also overexpress HSPs, which are frequently associated with resistance to therapy. HSPs have therefore been proposed as new therapeutic targets. Given the specific biology of hematological malignancies, it is essential to revise their role in this field, providing a more adaptable and comprehensive picture that would help design future clinical trials. To that end, this review will describe the different pathways and functions regulated by HSP27, HSP70, HSP90, and, not least, HSP110 in leukemias and lymphomas.
Mots clés
heat-shock protein, leukemia, lymphoma, targeted therapy
Référence
Cancers (Basel). 2023 02 3;15(3):